PL4074377T3 - Sposoby optymalizacji leczenia zaburzeń psychicznych za pomocą kannabidiolu i kompozycje farmaceutyczne zawierające kannabidiol - Google Patents
Sposoby optymalizacji leczenia zaburzeń psychicznych za pomocą kannabidiolu i kompozycje farmaceutyczne zawierające kannabidiolInfo
- Publication number
- PL4074377T3 PL4074377T3 PL21167887.5T PL21167887T PL4074377T3 PL 4074377 T3 PL4074377 T3 PL 4074377T3 PL 21167887 T PL21167887 T PL 21167887T PL 4074377 T3 PL4074377 T3 PL 4074377T3
- Authority
- PL
- Poland
- Prior art keywords
- cannabidiol
- optimizing
- treatment
- methods
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21167887.5A EP4074377B1 (en) | 2021-04-12 | 2021-04-12 | Methods for optimizing treatment of mental disorders with cannabidiol and pharmaceutical compositions comprising cannabidiol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4074377T3 true PL4074377T3 (pl) | 2025-08-18 |
Family
ID=75477957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21167887.5T PL4074377T3 (pl) | 2021-04-12 | 2021-04-12 | Sposoby optymalizacji leczenia zaburzeń psychicznych za pomocą kannabidiolu i kompozycje farmaceutyczne zawierające kannabidiol |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240192237A1 (pl) |
| EP (2) | EP4541350A3 (pl) |
| JP (1) | JP7634777B2 (pl) |
| CN (1) | CN117320702A (pl) |
| BR (1) | BR112023020839A2 (pl) |
| CA (1) | CA3214976A1 (pl) |
| ES (1) | ES3032936T3 (pl) |
| HR (1) | HRP20250698T1 (pl) |
| HU (1) | HUE071635T2 (pl) |
| PL (1) | PL4074377T3 (pl) |
| SM (1) | SMT202500224T1 (pl) |
| WO (1) | WO2022218930A2 (pl) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3302437T4 (da) | 2015-05-28 | 2026-02-23 | Fresh Cut Dev Llc | Stabile cannabinoidformuleringer |
| CN106074464A (zh) * | 2016-06-14 | 2016-11-09 | 云南瑞酚生物科技有限公司 | 大麻二酚在制备治疗痛风药物中的应用 |
| EP3724657A4 (en) | 2017-12-15 | 2021-12-29 | Bomi, Llc | Anti-cannabidiol antibody and uses thereof |
| US11179340B2 (en) * | 2017-12-29 | 2021-11-23 | TGC Network LLC | Cannabidiol dosage form |
| US20200375911A1 (en) | 2019-06-03 | 2020-12-03 | Fresh Cut Development, Llc | Cannabidiol nanocrystal compositions |
| CN111991355B (zh) * | 2019-12-30 | 2023-06-23 | 云南汉盟制药有限公司 | 含纳米级大麻二酚的固体纳米粉组合物、制备方法及用途 |
-
2021
- 2021-04-12 PL PL21167887.5T patent/PL4074377T3/pl unknown
- 2021-04-12 EP EP25162573.7A patent/EP4541350A3/en active Pending
- 2021-04-12 ES ES21167887T patent/ES3032936T3/es active Active
- 2021-04-12 EP EP21167887.5A patent/EP4074377B1/en active Active
- 2021-04-12 HU HUE21167887A patent/HUE071635T2/hu unknown
- 2021-04-12 HR HRP20250698TT patent/HRP20250698T1/hr unknown
- 2021-04-12 SM SM20250224T patent/SMT202500224T1/it unknown
-
2022
- 2022-04-11 BR BR112023020839A patent/BR112023020839A2/pt unknown
- 2022-04-11 CA CA3214976A patent/CA3214976A1/en active Pending
- 2022-04-11 US US18/286,526 patent/US20240192237A1/en active Pending
- 2022-04-11 JP JP2024505493A patent/JP7634777B2/ja active Active
- 2022-04-11 WO PCT/EP2022/059648 patent/WO2022218930A2/en not_active Ceased
- 2022-04-11 CN CN202280027887.6A patent/CN117320702A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HUE071635T2 (hu) | 2025-09-28 |
| JP7634777B2 (ja) | 2025-02-21 |
| BR112023020839A2 (pt) | 2023-12-12 |
| EP4074377B1 (en) | 2025-03-12 |
| EP4541350A3 (en) | 2025-10-15 |
| ES3032936T3 (en) | 2025-07-29 |
| HRP20250698T1 (hr) | 2025-09-12 |
| EP4541350A2 (en) | 2025-04-23 |
| EP4074377C0 (en) | 2025-03-12 |
| WO2022218930A2 (en) | 2022-10-20 |
| JP2024514716A (ja) | 2024-04-02 |
| US20240192237A1 (en) | 2024-06-13 |
| CN117320702A (zh) | 2023-12-29 |
| EP4074377A1 (en) | 2022-10-19 |
| CA3214976A1 (en) | 2022-10-20 |
| WO2022218930A3 (en) | 2023-01-05 |
| SMT202500224T1 (it) | 2025-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289975A (en) | Use of cannabidiol in the treatment of dravet syndrome | |
| MX380767B (es) | Métodos para reducir el riesgo cardiovascular. | |
| MX376835B (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| SI3377637T1 (sl) | Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože | |
| CL2015003442A1 (es) | Derivados heterociclicos | |
| MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
| PH12016500862A1 (en) | Autotaxin inhibitor compounds | |
| BR112017027836A2 (pt) | método para o tratamento de inflamação usando compostos naturais e/ou dieta | |
| EP2849738A4 (en) | HIGH-POWDER PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF LUNG DISEASES | |
| EP3952840A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL BEHAVIOR COGNITIVE DISORDERS | |
| EP3672587A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| PL3956310T3 (pl) | <div>MODYFIKOWANE POCHODNE AMINOKWASÓW DO LECZENIA CHORÓB NEUROLOGICZNYCH I WYBRANYCH ZABURZEŃ PSYCHICZNYCH</div> | |
| EP4426291A4 (en) | Indolizine compounds for the treatment of mental disorders or for mental improvement | |
| EP3581175A4 (en) | PREPARATION FOR THE ADMINISTRATION OF A DRUG FOR THE TREATMENT OF MENTAL ILLNESSES OR CENTRAL NERVOUS SYSTEM DISORDERS | |
| EP4008718C0 (en) | HETEROARYLAMIDOPYRIDINOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING AUTOIMMUNE DISEASE | |
| EP3566702A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ALLERGIC DISEASES SUCH AS ASTHMA OR ATOPIA, CONSISTING OF BAICALEIN AS THE ACTIVE SUBSTANCE | |
| IL279745A (en) | Methods for treating or preventing conformation diseases and methods for drug screening | |
| EP4058017A4 (en) | MEDICINAL FORMULATIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| EP3570835A4 (en) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF IMMUNINFLAMMABLE DERMAL DISEASES | |
| BR112018071972A2 (pt) | métodos para tratamento ou prevenção de uma doença ou distúrbio de fígado, para tratamento de câncer de fígado e para tratamento de inflamação no fígado, trato biliar ou pâncreas de um animal, alfa-defensina e/ou ss-defensina de mamífero e/ou uma catelicidina e/ou um análogo de glp-1, e, uso dos mesmos. | |
| BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
| EP3518951A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ORTHOPEDIC COMPLAINTS | |
| EP3552632A4 (en) | MEDICINAL COMPOSITION FOR TREATING AND PREVENTING CHRONIC DISEASE | |
| IL308083A (en) | Methods and compositions for treatment of diabetic retinopathy and related conditions | |
| CL2021000858A1 (es) | Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento |